Vontobel Holding Ltd. Sells 2,435 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 40.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,583 shares of the biopharmaceutical company’s stock after selling 2,435 shares during the period. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $884,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ALNY. Toth Financial Advisory Corp purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $25,000. Burkett Financial Services LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth about $37,000. CoreCap Advisors LLC increased its position in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 134 shares during the period. Keating Financial Advisory Services Inc. purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $42,000. Finally, SHP Wealth Management purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $43,000. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ALNY shares. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Stifel Nicolaus dropped their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Barclays cut their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Finally, Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $364.95.

Alnylam Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ ALNY opened at $230.71 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a market capitalization of $30.87 billion, a P/E ratio of 42.88 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $490.05. The business has a fifty day moving average price of $239.87 and a 200 day moving average price of $272.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the company earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.66 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.